{"id":1682,"date":"2019-11-14T22:18:33","date_gmt":"2019-11-14T19:18:33","guid":{"rendered":"http:\/\/www.internalmed-journal.in.ua\/?p=1682"},"modified":"2020-03-23T15:54:59","modified_gmt":"2020-03-23T12:54:59","slug":"%d0%b4%d0%b8%d0%b0%d0%b3%d0%bd%d0%be%d1%81%d1%82%d0%b8%d0%ba%d0%b0-%d0%b8-%d0%bb%d0%b5%d1%87%d0%b5%d0%bd%d0%b8%d0%b5-%d1%81%d1%82%d0%b0%d0%b1%d0%b8%d0%bb%d1%8c%d0%bd%d0%be%d0%b9-%d0%b8%d1%88%d0%b5","status":"publish","type":"post","link":"http:\/\/www.internalmed-journal.in.ua\/en\/archives\/1682","title":{"rendered":"Diagnosis and treatment of stable coronary heart disease in the practice\u00a0of a family doctor"},"content":{"rendered":"

Prof. O.M. Korzh<\/strong><\/p>\n

Kharkiv Medical Academy of Postgraduate Education<\/strong><\/p>\n

Among atherosclerosis-related cardiovascular diseases, chronic ischemic heart disease (CHD), in particular angina, is the most common form. Coronary heart disease is a myocardial lesion that develops as a result of animbalance between the coronary circulation and the metabolic needs of the heart muscle. At present, there aregood opportunities not only to use therapy with proven effectiveness aimed at reducing the risk of complications,including the development of fatal outcomes, but also more effective drug treatment of angina (ischemia), whichimproves quality of life. According to the recommendations for the management of patients with stable coronaryheart disease, drugs with a proven positive effect on the prognosis for this disease, which are mandatory for thepurpose, if there are no direct contraindications to their admission, as well as a large group of anti-anginal oranti-ischemic drugs are included in the scheme of drug therapy.<\/p>\n

Key Words:<\/strong> coronary heart disease, angina, family doctor.<\/p>\n

https:\/\/dx.doi.org\/10.15407\/internalmed2019.02.063<\/a><\/p>\n

Download.PDF<\/a><\/strong><\/p>\n

For citing:<\/strong><\/p>\n

    \n
  1. \u041a\u043e\u0440\u0436, \u041e.\u041c. \u0414\u0456\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u0456 \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u044f \u0441\u0442\u0430\u0431\u0456\u043b\u044c\u043d\u043e\u0457 \u0456\u0448\u0435\u043c\u0456\u0447\u043d\u043e\u0457 \u0445\u0432\u043e\u0440\u043e\u0431\u0438 \u0441\u0435\u0440\u0446\u044f \u0432 \u043f\u0440\u0430\u043a\u0442\u0438\u0446\u0456 \u0441\u0456\u043c\u0435\u0439\u043d\u043e\u0433\u043e \u043b\u0456\u043a\u0430\u0440\u044f \/\/ \u0421\u0445\u0456\u0434\u043d\u043e\u0454\u0432\u0440\u043e\u043f\u0435\u0439\u0441\u044c\u043a\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b \u0432\u043d\u0443\u0442\u0440\u0456\u0448\u043d\u044c\u043e\u0457 \u0442\u0430 \u0441\u0456\u043c\u0435\u0439\u043d\u043e\u0457 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0438. – 2019. – \u2116 2. – \u0421. 63-68. doi: 10.15407\/internalmed2019.02.063<\/li>\n
  2. Korzh OM. [Diagnosis and treatment of stable coronary heart disease in the practice of a family doctor]. Shidnoevr. z. vnutr. simejnoi med. 2019;2:63-68. doi: 10.15407\/internalmed2019.02.063. Ukrainian.<\/li>\n<\/ol>\n

    References:<\/p>\n

    1. The Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies- Cardiovascular (ACCESS CV). Sharing Data from Cardiovascular Clinical Trials- A Proposal. New England Journal of Medicine. 2016;375:407-409. English. DOI: 10.1056\/nejmp1605260
    \nhttps:\/\/doi.org\/10.1056\/NEJMp1605260<\/p>\n

    2. 2013 ESC Guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34:2949-3003. English. DOI: 10.1093\/eurheartj\/eht296
    \nhttps:\/\/doi.org\/10.1093\/eurheartj\/eht296<\/p>\n

    3. 2016 ESC\/EAS Guidelines for the \u043canagement of dyslipidaemias. European Heart Journal. 2016;37:2999-3058. English. DOI: 10.1093\/eurheartj\/ehw272
    \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehw272<\/p>\n

    4. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis \u0412S, Ophuis TO, Jukema JW, GM De Ferrari, Ruzyllo W, De Lucca P, Im KyungAh, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 2015;372:2387-2397. English. DOI: 10.1056\/NEJMoa1410489
    \nhttps:\/\/doi.org\/10.1056\/NEJMoa1410489<\/p>\n

    5. Mombelli G, Castelnuovo S, Pavanello C. Potential of PCSK9 as a new target for the management of LDL cholesterol Research Reports in Clinical Cardiology. 2015;6:73-86. English. DOI: 10.2147\/RRCC.S52961.
    \nhttps:\/\/doi.org\/10.2147\/RRCC.S52961<\/p>\n

    6. Sabatine MS, Giugliano RP, Pedersen TR. Evolocumab in patients with cardiovascular disease. New England Journal of Medicine. 2017;377:785-788. English. DOI: 10.1056\/nejmc1708587.
    \nhttps:\/\/doi.org\/10.1056\/NEJMc1708587<\/p>\n

    7. Sundstro\u0308m J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events. A Swedish Nationwide, Population- Based Cohort Study. Circulation. 2017;136:1183-1192. English. DOI: 10.1161\/CIRCULATIONAHA.117.028321.
    \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028321<\/p>\n

    8. 2017 ESC Guidelines for the management of acute myocardial infarction in patients pre- senting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39:119-177. English. DOI: 10.1093\/eurheartj\/ehx393V.<\/p>\n

    9. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal. 2018;39:763-821. English. DOI: 10.1093\/eurheartj\/ehy045.
    \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehy045<\/p>\n

    10. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal. 2016;37:390-399. English. DOI: 10.1093\/eurheartj\/ehv443.
    \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehv443<\/p>\n

    11. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA,Parkhomenko AN, Ertl G, St\u00f6rk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ,Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM,Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Bruns NC, Misselwitz F, Chen E, Leong D, Yusuf S. Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine. 2017;377:1319-1330. English. DOI: 10.1056\/NEJMoa1709118
    \nhttps:\/\/doi.org\/10.1056\/NEJMoa1709118<\/p>\n

    12. Evans M, Carrero JJ, Szummer K, Akerblom A. Angiotensin- Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction. Journal of the American College of Cardiology. 2016;67:1687-1697. English. DOI: 10.1016\/j.jacc.2016.01.050.
    \nhttps:\/\/doi.org\/10.1016\/j.jacc.2016.01.050<\/p>\n","protected":false},"excerpt":{"rendered":"

    Prof. O.M. Korzh Kharkiv Medical Academy of Postgraduate Education Among atherosclerosis-related cardiovascular diseases, chronic ischemic heart disease (CHD), in particular angina, is the most common form. Coronary heart disease is a myocardial lesion that develops as a result of animbalance between the coronary circulation and the metabolic needs of the heart muscle. At present, there…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9,43,49],"tags":[],"translation":{"provider":"WPGlobus","version":"2.12.2","language":"en","enabled_languages":["uk","en","ru"],"languages":{"uk":{"title":true,"content":true,"excerpt":false},"en":{"title":true,"content":true,"excerpt":false},"ru":{"title":true,"content":true,"excerpt":false}}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/1682"}],"collection":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/comments?post=1682"}],"version-history":[{"count":4,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/1682\/revisions"}],"predecessor-version":[{"id":1892,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/1682\/revisions\/1892"}],"wp:attachment":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/media?parent=1682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/categories?post=1682"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/tags?post=1682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}